Non-Muscle Invasive Bladder Urothelial Carcinoma
13 clinical trials · Condition
◉ Watch Non-Muscle Invasive Bladder Urothelial Carcinoma
| Record | Firm | Date |
|---|---|---|
| Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable (NCT04730232) | Tianjin Medical University Second Hospital | 2020-12-27 |
| Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer (NCT05946369) | Ain Shams University | 2020-05-01 |
| Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (NCT04164082) | National Cancer Institute (NCI) | 2020-03-18 |
| Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer (NCT06020807) | Nucleix Ltd. | 2019-09-05 |
| Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. (NCT06167356) | IRCCS San Raffaele | 2013-11-27 |
Track Non-Muscle Invasive Bladder Urothelial Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.